Lisata Therapeutics, Inc. filed a Form 8-K on November 9, 2026, reporting the results of its 2026 annual meeting of stockholders, at which six of seven voted proposals were approved and one proposal regarding preferred stock conversion was adjourned to November 30, 2026.
Key Highlights
- Quorum reached: Of 10,804,066 shares outstanding as of the record date, 8,172,668 shares, or 75.64%, were present or represented by proxy at the annual meeting.
- 2026 Equity Incentive Plan approved: The plan carries an initial share reserve of 44,764,472 shares of common stock, with an automatic annual increase of 5% of outstanding shares each January 1, beginning January 1, 2027.
- 2026 ESPP approved: The Employee Stock Purchase Plan has an initial share reserve of 3,730,372 shares, with automatic annual increases through January 1, 2036.
- Reverse stock split approved: Stockholders approved an amendment allowing the board to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15, without further stockholder approval.
- Conversion Proposal adjourned: The vote on issuance of shares upon conversion of Series C Non-Voting Convertible Preferred Stock was adjourned, with the meeting reconvened solely for that purpose on November 30, 2026.
- Directors elected: Cynthia L. Flowers and Dr. Ted W. Love, M.D. were elected as Class I directors to serve until the 2029 Annual Meeting of Stockholders.
- Auditor ratified: Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 7,851,870 votes in favor.
Lisata Therapeutics 2026 Annual Meeting: Voting Results and Plan Details
According to the filing, Lisata Therapeutics, Inc. (NASDAQ:LSTA) held its 2026 annual meeting of stockholders on November 9, 2026. Stockholders voted on seven of eight proposals described in the company's definitive proxy statement filed with the SEC on October 19, 2026. The board of directors had previously approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan on October 7, 2026, subject to stockholder approval, which was subsequently obtained at the meeting.
The 2026 Equity Incentive Plan received 2,924,154 votes for and 1,552,345 votes against, with 192,425 abstentions and 3,503,744 broker non-votes. The plan's initial share reserve of 44,764,472 shares is subject to automatic annual increases of 5% of "outstanding shares," a term the filing defines to include common stock issued and outstanding, shares issuable upon exercise of outstanding pre-funded warrants at nominal exercise prices, and shares underlying outstanding preferred stock on an as-converted basis. The 2026 ESPP received 3,374,775 votes for and 1,119,638 votes against, with its automatic increase provisions running through January 1, 2036.
The proposal to approve issuance of shares upon conversion of the company's Series C Non-Voting Convertible Preferred Stock - which the filing states would represent more than 20% of shares outstanding and result in a change of control under Nasdaq Listing Rules 5635(a) and 5635(b) - was adjourned without a vote. The filing states the annual meeting will be reconvened solely with respect to that proposal on November 30, 2026, and that the company will report voting results in a subsequent Form 8-K following the reconvened meeting.
What Was Disclosed
Lisata Therapeutics reported the results of its November 9, 2026 annual meeting, including approval of two new equity plans, a reverse stock split authorization, director elections, and auditor ratification, while adjourning one contested conversion proposal to November 30, 2026.



Please wait processing your request...